Corticosteroid design for the treatment of asthma

Structural insights and the therapeutic potential of soft corticosteroids

Nicholas Bodor, Peter Buchwald

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Inhaled and intranasal corticosteroids (ICSs) still are the most effective treatment available for allergic airway diseases and are likely to remain the cornerstone of managing persistent asthma/allergic rhinitis in the foreseeable future. Even if the therapeutic index of this class increased significantly with the introduction of newer corticosteroids, and even if new therapeutic potentials are beginning to emerge with our increasing understanding of the mechanisms of asthma, chronic obstructive pulmonary disease, and rhinitis, corticosteroid development still remains a very important field for drug designers. After a brief review of issues related to the structure-activity relationships of glucocorticoids and the main determinants of their receptor-binding affinity at the glucocorticoid receptor, the main focus of the present article will be on the development of soft corticosteroids, as they are particularly well suited to separate local activity from systemic side effects, which still is an important issue for ICSs. Design consideration required in the search for safe and effective soft drugs on one hand, and safe and effective ICSs on the other hand, will be briefly discussed and illustrated with a number of cases, in particular, with that of loteprednol etabonate and etiprednol dicloacetate, soft corticosteroids that are being developed for a full spectrum of therapeutic applications including asthma and allergic rhinitis.

Original languageEnglish
Pages (from-to)3241-3260
Number of pages20
JournalCurrent Pharmaceutical Design
Volume12
Issue number25
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Adrenal Cortex Hormones
Asthma
Therapeutics
Designer Drugs
Glucocorticoid Receptors
Structure-Activity Relationship
Rhinitis
Chronic Obstructive Pulmonary Disease
Glucocorticoids
Pharmaceutical Preparations
Allergic Rhinitis

Keywords

  • Glucocorticoid
  • Itrocinonide
  • Loteprednol etabonate
  • Prednisolone
  • Receptor-binding affinity;
  • Soft Corticosteroid Designs

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Corticosteroid design for the treatment of asthma : Structural insights and the therapeutic potential of soft corticosteroids. / Bodor, Nicholas; Buchwald, Peter.

In: Current Pharmaceutical Design, Vol. 12, No. 25, 01.09.2006, p. 3241-3260.

Research output: Contribution to journalArticle

@article{4078258845b048b493ced1911fed8ccd,
title = "Corticosteroid design for the treatment of asthma: Structural insights and the therapeutic potential of soft corticosteroids",
abstract = "Inhaled and intranasal corticosteroids (ICSs) still are the most effective treatment available for allergic airway diseases and are likely to remain the cornerstone of managing persistent asthma/allergic rhinitis in the foreseeable future. Even if the therapeutic index of this class increased significantly with the introduction of newer corticosteroids, and even if new therapeutic potentials are beginning to emerge with our increasing understanding of the mechanisms of asthma, chronic obstructive pulmonary disease, and rhinitis, corticosteroid development still remains a very important field for drug designers. After a brief review of issues related to the structure-activity relationships of glucocorticoids and the main determinants of their receptor-binding affinity at the glucocorticoid receptor, the main focus of the present article will be on the development of soft corticosteroids, as they are particularly well suited to separate local activity from systemic side effects, which still is an important issue for ICSs. Design consideration required in the search for safe and effective soft drugs on one hand, and safe and effective ICSs on the other hand, will be briefly discussed and illustrated with a number of cases, in particular, with that of loteprednol etabonate and etiprednol dicloacetate, soft corticosteroids that are being developed for a full spectrum of therapeutic applications including asthma and allergic rhinitis.",
keywords = "Glucocorticoid, Itrocinonide, Loteprednol etabonate, Prednisolone, Receptor-binding affinity;, Soft Corticosteroid Designs",
author = "Nicholas Bodor and Peter Buchwald",
year = "2006",
month = "9",
day = "1",
doi = "10.2174/138161206778194132",
language = "English",
volume = "12",
pages = "3241--3260",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "25",

}

TY - JOUR

T1 - Corticosteroid design for the treatment of asthma

T2 - Structural insights and the therapeutic potential of soft corticosteroids

AU - Bodor, Nicholas

AU - Buchwald, Peter

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Inhaled and intranasal corticosteroids (ICSs) still are the most effective treatment available for allergic airway diseases and are likely to remain the cornerstone of managing persistent asthma/allergic rhinitis in the foreseeable future. Even if the therapeutic index of this class increased significantly with the introduction of newer corticosteroids, and even if new therapeutic potentials are beginning to emerge with our increasing understanding of the mechanisms of asthma, chronic obstructive pulmonary disease, and rhinitis, corticosteroid development still remains a very important field for drug designers. After a brief review of issues related to the structure-activity relationships of glucocorticoids and the main determinants of their receptor-binding affinity at the glucocorticoid receptor, the main focus of the present article will be on the development of soft corticosteroids, as they are particularly well suited to separate local activity from systemic side effects, which still is an important issue for ICSs. Design consideration required in the search for safe and effective soft drugs on one hand, and safe and effective ICSs on the other hand, will be briefly discussed and illustrated with a number of cases, in particular, with that of loteprednol etabonate and etiprednol dicloacetate, soft corticosteroids that are being developed for a full spectrum of therapeutic applications including asthma and allergic rhinitis.

AB - Inhaled and intranasal corticosteroids (ICSs) still are the most effective treatment available for allergic airway diseases and are likely to remain the cornerstone of managing persistent asthma/allergic rhinitis in the foreseeable future. Even if the therapeutic index of this class increased significantly with the introduction of newer corticosteroids, and even if new therapeutic potentials are beginning to emerge with our increasing understanding of the mechanisms of asthma, chronic obstructive pulmonary disease, and rhinitis, corticosteroid development still remains a very important field for drug designers. After a brief review of issues related to the structure-activity relationships of glucocorticoids and the main determinants of their receptor-binding affinity at the glucocorticoid receptor, the main focus of the present article will be on the development of soft corticosteroids, as they are particularly well suited to separate local activity from systemic side effects, which still is an important issue for ICSs. Design consideration required in the search for safe and effective soft drugs on one hand, and safe and effective ICSs on the other hand, will be briefly discussed and illustrated with a number of cases, in particular, with that of loteprednol etabonate and etiprednol dicloacetate, soft corticosteroids that are being developed for a full spectrum of therapeutic applications including asthma and allergic rhinitis.

KW - Glucocorticoid

KW - Itrocinonide

KW - Loteprednol etabonate

KW - Prednisolone

KW - Receptor-binding affinity;

KW - Soft Corticosteroid Designs

UR - http://www.scopus.com/inward/record.url?scp=33748566568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748566568&partnerID=8YFLogxK

U2 - 10.2174/138161206778194132

DO - 10.2174/138161206778194132

M3 - Article

VL - 12

SP - 3241

EP - 3260

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 25

ER -